LRRK2 and Parkinson disease: In line with this, the largest studies of DBS in LRRK2 patients show no significant differences in outcome compared to non-carriers.28,29 Some conflicting evidence is presented in small studies and case reports, but taken together we see no current rationale for LRRK2 status to impact clinical considerations concerning DBS treatment in PD.